Health
Oxford, Serum Institute Partner for Bundibugyo Ebola Vaccine Trials
David Hale·
109 articles
FDA-approved oral AML therapy allows older patients to avoid monthly infusion visits, marking a significant advance in p…
FDA grants Pasithea ALS drug PAS-004 rare-disease status on June 3, 2026, accelerating its development for the devastati…
A new study published on June 2, 2026, reveals childhood maltreatment significantly increases the risk of intimate partn…
FDA approves new prostate cancer companion diagnostics, FoundationOne CDx and Liquid CDx, for targeted mCRPC therapy.
Idorsia’s glycan-targeting C diff. vaccine maintains positive clinical trajectory, offering significant hope against thi…
WHO advises on Bundibugyo virus treatments and vaccines as an outbreak in DRC and Uganda prompts urgent clinical trial r…
A new HIV treatment from Imperial College London could allow patients to go drug-free for up to two years, reducing dail…
Doctors Without Borders launches an urgent response to an Ebola outbreak 2026, highlighting persistent global health cha…
A new study led by Professor Helen Milroy reveals Aboriginal mental health workers are central to culturally safe patien…
A Bundibugyo virus outbreak in DR Congo presents a unique challenge due to the lack of approved vaccines and treatments,…
Advancements in minimally invasive vein procedures revolutionize vascular care, offering safer, more efficient treatment…